InvestorsHub Logo
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Re: geocappy1 post# 152339

Tuesday, 12/17/2013 4:16:11 AM

Tuesday, December 17, 2013 4:16:11 AM

Post# of 346353
geocappy, in light of the 'discussion' part of this document I think sualco's expectations are in the good direction.

You may remember that I wrote on several occasions that I don't see Bavi as a cure for cancer either but that I think it is a substance that will contribute majorly to the cure of cancer. This puts it in a broader perspective then just a drug that does something for a specific condition.

My "Peregrine Pharmaceuticals the Microsoft of Biotechnology" is based on that believe and actually my complete initial interest in PPHM was based on the "conceptual" approach of solving problems (the generic use of Cotara in all solid cancers and Bavi for many cancer, viral and other conditions that use PS as a defence to keep our operating system from being activated). The conceptual approach of making a substance that keeps PS from accessing the immune cell receptors by which it disables the immune system from taking broader action is therefore very efficient because it re-enables our natural defence.

And since ALL methods that we know today to combat tumours result in PS exposure (these methods are surgery and cutting away the tumour and its periphery, chemo, radio and Cotara - localized delivery - all resulting in cell damage at some extend and therefore all resulting in PS exposure) they ALL benefit from a substance as Bavi that keeps PS from being abused (because for apoptic cells PS must of course avoid that daily systemic immune reaction would occur for the clean-up of death cells which happens mostly at night when we sleep with a slight temperature change).

2aG4 reactivates the native and ADAPTIVE immune system!

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News